Transatlantic Innovations in Cancer Drug Research
Jimmy Fund Auditorium
35 Binney St, Boston, MA 02115
overview
Join world-leading experts from Dana-Farber Cancer Institute (Boston) and Gustave Roussy Cancer Campus (Paris) for the 5th Annual Oncology Innovation Meeting - a 1-day event dedicated to the next frontiers in cancer drug research.
What’s on the agenda?
- Epigenetic therapies: advancing precision oncology
- Microbiome-driven immunity: unlocking host-microbe power
- Cellular pathway reprogramming: new strategies for treatment
Discover breakthrough technologies and transformative approaches that promise to redefine cancer care worldwide.
Why attend?
- ✔ Learn from global pioneers
- ✔ Explore emerging trends in oncology drug development
- ✔ Connect across continents
Join us in person or online for this landmark event. Don’t miss your chance to be part of the conversation shaping tomorrow’s cancer treatments.
Click the video to learn more.
There is no registration fee to attend this event.
faculty
Program Chair, Moderator
Toni K. Choueiri, MD
Director, The Lank Center for Genitourinary Oncology
Medical Director, International Strategic Initiatives
Dana-Farber Cancer Institute
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
The Jerome and Nancy Kohlberg Chair
and Professor of Medicine
Harvard Medical School
Boston, Massachusetts, United States
Program Chair, Moderator
Laurence Albiges, MD, PhD
Professor of Medical Oncology
Chair of Medical Oncology Department
Gustave Roussy Institute
Villejuif, France
Keynote Speaker
Alice Shaw, MD, PhD
Chief, Strategic Partnerships
Physician, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts, United States
Moderator
Fabrice Barlesi, MD, PhD
General Director
Gustave Roussy
Professor of Medicine
Université Paris-Saclay
Villejuif, France
Moderator
Eric Fischer, PhD
Joseph Deitch Family Chair & Director
Chemical Biology Program
Dana-Farber Cancer Institute
Professor of Biological Chemistry and Molecular Pharmacology
Harvard Medical School,
Boston, Massachusetts, United States
Moderator
Wendy S. Garrett, MD, PhD
Irene Heinz Given Professor of Immunology and Infectious Diseases
Department of Immunology and Infectious Diseases
Harvard T.H. Chan School of Public Health
Professor of Medicine
Harvard Medical School
Boston, Massachusetts, United States
Moderator
Kevin Haigis, PhD
Professor of Medicine
Harvard Medical School
Chief Scientific Officer/Principal Investigator
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Moderator
Laurie Menger, PhD
Group Leader, Advanced T-Cell Therapy
Gustave Roussy Institute
Villejuif, France
Moderator
Patrick Therasse, MD, PhD
Managing Director
L’Institut Servier
Paris, France
AGENDA
March 27, 2026
09:00 - 9:10 AM Opening and Welcome
Toni K. Choueiri, MD (Program Chair, Moderator)
Laurence Albiges, MD, PhD (Program Chair, Moderator)
Patrick Therasse, MD, PhD (Moderator)
09:10 - 10:10 AM Session 1 | Drug Repurposing and Reformulation
Eric Fischer, PhD (Moderator)
Laurence Albiges, MD, PhD (Moderator)
Targeting Non-Canonical PI3K Signaling Through Drug Repositioning
Andrew A. Lane, MD, PhD
Discovery and Development of Drugs for Rare Cancers: Challenges and Opportunities
George D. Demetri, MD
Use of Pharmaceutical Sciences to Meet Unmet Needs in Hospitals (New Formulation and Reformulation)
Maxime Annereau, PhD
Session includes a 15-min Q&A
10:10 - 11:10 AM Keynote Address
Fabrice Barlesi, MD, PhD (Moderator)
Toni K. Choueiri, MD (Moderator)
Targeting the RAS Oncogene in Cancer
Alice Shaw, MD, PhD
Session includes a 15-min Q&A and 15-min break
BREAK 10:55 - 11:10 AM
11:10 AM - 12:10 PM Session 2 | Cell Therapies Beyond T Cells and Role of Microbiome in Shaping Immunity
Wendy S. Garrett, MD (Moderator)
Patrick Therasse, MD, PhD (Moderator)
NK Cell Therapy
Eric Vivier, DVM, PhD
Therapies Targeting Cancer-Associated Bacteria
Carolina Alves Costa Silva, MD, PhD
Microbiome and Immunity
Wendy S. Garrett, MD, PhD
Session includes a 15-min Q&A and 50-min break
LUNCH 12:10 - 13:00 PM
13:00 - 14:00 PM Session 3 | Epigenetics
Laurence Albiges, MD, PhD (Moderator)
Kevin Haigis, PhD (Moderator)
Initiation and Progression of IDH-Mutant Gliomas
Brad Bernstein, MD, PhD
Menin Inhibitors: From Bench to Bedside to Bench
Scott A. Armstrong, MD, PhD
Targeting Chromatin Regulatory Machinery in Human Cancer
Cigall Kadoch, PhD
Session includes a 15-min Q&A
14:00 - 15:15 PM Session 4 | Reprogramming and Rewiring
Eric Fischer, PhD (Moderator)
Laurie Menger, PhD (Moderator)
Transient Epigenetic Reprogramming of T-Cell Therapies
Laurie Menger, PhD
Protein Engineering Approaches to Rewire Cells as a Therapy
Xin Zhou, PhD
Genetically Modified Monocytes as a Therapy (Cell Therapy Using Macrophages)
Jean-Luc Perfettini, PhD
Session includes a 15-min Q&A and 15-min break
BREAK 15:00 - 15:15 PM
15:15 - 16:15 PM Session 5 | Fellowship Exchange Program (Dana-Farber Cancer Institute and Gustave Roussy)
Toni K. Choueiri, MD (Program Chair, Moderator)
Patrick Therasse, MD, PhD (Moderator)
DNA-PK inhibition and Targeting PSMA
Alice Bernard-Tessier, MD
Clinical Utility of Cell-Free DNA Epigenomic Profiling in Cancer
Damien Vasseur, PharmD, PhD
Germline Predisposition of Immune-Related Adverse Events
François-Xavier Danlos, MD, PhD
Session includes a 15-min Q&A
16:15 - 16:30 PM | Closing Remarks
Chairs to Close
Toni K. Choueiri, MD (Program Chair, Moderator)
Laurence Albiges, MD, PhD (Program Chair, Moderator)